Capecitabine, 99%, reagent, for R&D that is converted to its active metabolite, 5-FU, by thymidine phosphorylase

Name: Capecitabine, 99%, reagent, for R&D that is converted to its active metabolite, 5-FU, by thymidine phosphorylase | 154361-50-9
Brand: J&K Chemical
SKU: JK392078_250_MG
Price: 89.9 USD
Availability: OutOfStock

Cat. No JK392078_250_MG

Vendor: J&K Chemical

Product Information

Product Name

Capecitabine, 99%, reagent, for R&D that is converted to its active metabolite, 5-FU, by thymidine phosphorylase

Brand Name

J&K

Product Number

392078

CAS

154361-50-9

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

60953

IUPAC Name

pentyl N-1-(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl-5-fluoro-2-oxopyrimidin-4-ylcarbamate

InChI Key

GAGWJHPBXLXJQN-UORFTKCHSA-N

SMILES

CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C@H2C@@H(C@@H(C@H(O2)C)O)O

Safety Information

Storage Condition

Store at 2-8℃

References Data Source From Pubchem

[Current concepts of total neoadjuvant therapy for rectal cancer]

Publication Name: Chirurgie (Heidelberg, Germany)

Publication Date: 2026-07

DOI: 10.1007/s00104-026-02461-w

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

Publication Name: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Publication Date: 2026-06-18

DOI: 10.1007/s10120-025-01641-7|10.1007/s10120-026-01772-5

[Biomarker testing for carcinomas of the upper gastrointestinal tract]

Publication Name: Pathologie (Heidelberg, Germany)

Publication Date: 2026-05

DOI: 10.1007/s00292-025-01506-x

[Embolic occlusions of the right hand: an interdisciplinary challenge]

Publication Name: Innere Medizin (Heidelberg, Germany)

Publication Date: 2026-04

DOI: 10.1007/s00108-025-02007-y

Good local control acquired by chemoradiation for inoperable adenocarcinoma of the anal canal with pagetoid spread: a report of two cases

Publication Name: International Cancer Conference Journal

Publication Date: 2025-09-29

DOI: 10.1007/s13691-025-00808-4

Capecitabine, 99%, reagent, for R&D that is converted to its active metabolite, 5-FU, by thymidine phosphorylase

Product Information

General Information

Safety Information

References Data Source From Pubchem

[Current concepts of total neoadjuvant therapy for rectal cancer]

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

[Biomarker testing for carcinomas of the upper gastrointestinal tract]

[Embolic occlusions of the right hand: an interdisciplinary challenge]

Good local control acquired by chemoradiation for inoperable adenocarcinoma of the anal canal with pagetoid spread: a report of two cases